血栓塞栓症(Thromboembolism)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thromboembolism Overview 8
Therapeutics Development 9
Pipeline Products for Thromboembolism – Overview 9
Pipeline Products for Thromboembolism – Comparative Analysis 10
Thromboembolism – Therapeutics under Development by Companies 11
Thromboembolism – Therapeutics under Investigation by Universities/Institutes 13
Thromboembolism – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thromboembolism – Products under Development by Companies 17
Thromboembolism – Products under Investigation by Universities/Institutes 18
Thromboembolism – Companies Involved in Therapeutics Development 19
Bayer AG 19
Cereno Scientific AB 20
CSL Limited 21
Daiichi Sankyo Company, Limited 22
Gamma Therapeutics, Inc. 23
Green Cross Corporation 24
Isis Pharmaceuticals, Inc. 25
Portola Pharmaceuticals, Inc. 26
Regado Biosciences, Inc. 27
Sanofi 28
Thromboembolism – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
betrixaban – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
C-3 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CSL-3F7 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
edoxaban tosylate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Gammarin – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GCC-2107 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ISIS-FXIRx – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Lysimab – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Protein for Thromboembolism and Blood Coagulation – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
REG-2 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
rivaroxaban – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
semuloparin – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit HDAC for Thromboembolism – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TAP-ANV – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
YG-001 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Thromboembolism – Recent Pipeline Updates 61
Thromboembolism – Dormant Projects 78
Thromboembolism – Discontinued Products 79
Thromboembolism – Product Development Milestones 80
Featured News & Press Releases 80
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 80
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 80
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 82
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 82
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 83
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 83
Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 84
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 85
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 86
May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90